Subscribe to Updates

    Get the latest news from Legacy Medi4!

    Our Picks

    Gene Expression in Neurons Solves a Brain Evolution Puzzle

    March 26, 2023

    Strange Signal From Decades Ago Hints at Hidden Oceans Orbiting Uranus : ScienceAlert

    March 26, 2023

    Here’s How to Rewire Your Brain So You Actually Look Forward to Mondays : ScienceAlert

    March 25, 2023

    Huge Study Finds Swathe of Genetic Risk Factors For Endometriosis : ScienceAlert

    March 25, 2023
    Facebook Twitter Instagram
    • Privacy Policy
    • Contact Us
    • About Us
    • Disclaimer
    Facebook Twitter Instagram YouTube
    Legacy Medi4Legacy Medi4
    • World News
    • Business
    • Entertainment
    • Health
    • Science
    • Sports
    • Technology
    Legacy Medi4Legacy Medi4
    Home»Business»Malaysian biotech CytoMed Therapeutics files for $10M US IPO
    Business

    Malaysian biotech CytoMed Therapeutics files for $10M US IPO

    Todd LivingstonBy Todd LivingstonNovember 18, 2022No Comments1 Min Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    The first to provide a hologram, a night panoramic view of the city of Bangkok.  A financial center for multinational companies in Asia.  The idea of ​​increasing growth is the IPO strategy.  Double exposure.

    Pictures are 2d images

    Malaysian Biotech CytoMed Therapeutics (GDTC) has raised $15M in a public offering.

    CytoMed did not state in writing the number and price of the units it intends to offer but indicated in the and written salary schedule that it wants to raise about $15M.

    The company hopes to list its shares on the Nasdaq under the symbol GDTC. Benchmark Co. and Axiom Capital Management are serving as bookrunners.

    Incorporated in Singapore, CytoMed does most of its operations in Malaysia. The company has been developing cell-based immunotherapies for the treatment of cancer. It expects to use the proceeds from the IPO to advance the two directors who will enter Phase 1 testing.

    A pre-clinical stage company, CytoMed is operating in the red. For the six months ended June 30, CytoMed reported a net loss of $1M and no cash flow.

    For more information on IPO News, see the IPO News SA website.

    Source link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    Todd Livingston

    Related Posts

    Corsair Gaming bumps 3% as holiday quarter tops forecasts (NASDAQ:CRSR)

    February 9, 2023

    META has rallied more than 40% so far in 2023. Is it still a buy here?

    February 9, 2023

    Analysts stay positive on Google AI after historic value wipeout (NASDAQ:GOOGL)

    February 9, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Gene Expression in Neurons Solves a Brain Evolution Puzzle

    March 26, 2023

    Strange Signal From Decades Ago Hints at Hidden Oceans Orbiting Uranus : ScienceAlert

    March 26, 2023

    Here’s How to Rewire Your Brain So You Actually Look Forward to Mondays : ScienceAlert

    March 25, 2023

    Huge Study Finds Swathe of Genetic Risk Factors For Endometriosis : ScienceAlert

    March 25, 2023

    Subscribe to Updates

    Get the latest news from Legacy Medi4!

    Our Picks

    Gene Expression in Neurons Solves a Brain Evolution Puzzle

    March 26, 2023

    Strange Signal From Decades Ago Hints at Hidden Oceans Orbiting Uranus : ScienceAlert

    March 26, 2023

    Here’s How to Rewire Your Brain So You Actually Look Forward to Mondays : ScienceAlert

    March 25, 2023

    Type above and press Enter to search. Press Esc to cancel.